Skip to main content

This website is intended for US healthcare professionals only.

INGREZZA® (valbenazine) capsules for adults with tardive dyskinesia (TD) Home Logo

INBRACE® Support Program for INGREZZA

Many paths, one goal: Access for every patient prescribed INGREZZA

Red and white INBRACE Support Program logo

With many paths to INGREZZA® (valbenazine) capsules, the INBRACE Support Program is committed to the goal of helping all patients get access to the medication they need

Call 1-84-INGREZZA (1-844-647-3992), 8 am to 8 pm ET, Monday through Friday, to learn more.

LEARN MORE TREATMENT FORM

$10 or less out-of-pocket is what most patients pay for INGREZZA1

Financial assistance options are available to help your patients start and stay on treatment

Now it’s easier than ever for your patients to access INGREZZA

INGREZZA coverage is approved for more than 8 of 10 patients nationwide1

$10 or less out-of-pocket is what most patients pay for INGREZZA1

Financial assistance options are available to help your patients start and stay on treatment

Now it’s easier than ever for your patients to access INGREZZA

INGREZZA coverage is approved for more than 8 of 10 patients nationwide1

Dedicated, field-based support to provide personalized access solutions

Our Regional Patient Access Managers (RPAMs) are available to help you and your office navigate access

Start your patients on INGREZZA right away

INGREZZA® (valbenazine) capsules packaging

INGREZZA SAMPLES

Request samples of INGREZZA today to start patients on treatment

REQUEST INFO

FREE TRIAL OFFER

Request a free one-month supply of INGREZZA for new patients

REQUEST TRIAL

The free trial is not contingent on a purchase of any kind. Product dispensed under this free trial program may not be submitted for reimbursement to any third-party payer. We reserve the right to modify or cancel the program at any time. Additional terms and conditions apply.

INGREZZA SAVINGS PROGRAM*

Eligible patients may pay as little as a $0 copay on their INGREZZA prescription

*This offer is valid only for patients with commercial (nongovernment-funded) insurance. Additional terms and conditions apply.

DOWNLOAD COPAY CARD

INGREZZA PATIENT ASSISTANCE PROGRAM†

Eligible patients with no insurance -or- no prescription coverage for INGREZZA may be able to receive their prescription at no cost

†Additional terms and conditions apply.

APPLY FOR ASSISTANCE

LOOKING FOR MORE ACCESS RESOURCES?

Download access-related forms and templates to help you and your practice

DOWNLOAD RESOURCES

REFERENCE:

  1. Measured by NDC; data on file as of Q3 2023. Neurocrine Biosciences, Inc.
+Expand-Collapse

Important Safety Information

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA, can increase the risk of depression and suicidal thoughts and

Important Information

INDICATION & USAGE

INGREZZA® (valbenazine) capsules and INGREZZA® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease.